Shanghai Kaibao Pharmaceutical Total Liabilities
Shanghai Kaibao Pharmaceutical total liabilities. Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has total liabilities worth CN¥308.94 Million CNY (≈ $45.21 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300039 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Kaibao Pharmaceutical (2006–2025)
Total liabilities of Shanghai Kaibao Pharmaceutical from 2006 to 2025. This chart illustrates how Shanghai Kaibao Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore Shanghai Kaibao Pharmaceutical (300039) investment intensity to see how much of total assets are deployed in long-term investments.
Shanghai Kaibao Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
USA | $1.33 Billion |
|
Gujarat Narmada Valley Fertilizers and Chemicals Limited
NSE:GNFC
|
India | Rs-91.15 Billion |
|
Fidus Investment Corp
NASDAQ:FDUS
|
USA | $702.16 Million |
|
SK Securities Co Ltd Preference Shares
KO:001515
|
Korea | ₩7.13 Trillion |
|
Annexon Inc
NASDAQ:ANNX
|
USA | $60.01 Million |
|
Scanfil Oyj
HE:SCANFL
|
Finland | €464.90 Million |
|
SKF India Limited
NSE:SKFINDIA
|
India | Rs7.50 Billion |
|
Nobia AB
ST:NOBI
|
Sweden | Skr8.09 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Shanghai Kaibao Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Shanghai Kaibao Pharmaceutical's balance sheet.
Liquidity & Leverage Metrics
Shanghai Kaibao Pharmaceutical Total Liabilities Ratios Explained
Shanghai Kaibao Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Kaibao Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Kaibao Pharmaceutical (2006–2025)
The table below shows the annual total liabilities of Shanghai Kaibao Pharmaceutical from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥359.64 Million ≈ $52.63 Million |
-13.43% |
| 2024-12-31 | CN¥415.45 Million ≈ $60.79 Million |
-24.02% |
| 2023-12-31 | CN¥546.82 Million ≈ $80.02 Million |
+9.75% |
| 2022-12-31 | CN¥498.24 Million ≈ $72.91 Million |
+60.25% |
| 2021-12-31 | CN¥310.90 Million ≈ $45.50 Million |
+4.00% |
| 2020-12-31 | CN¥298.96 Million ≈ $43.75 Million |
+9.51% |
| 2019-12-31 | CN¥273.01 Million ≈ $39.95 Million |
+4.10% |
| 2018-12-31 | CN¥262.26 Million ≈ $38.38 Million |
-16.55% |
| 2017-12-31 | CN¥314.26 Million ≈ $45.99 Million |
-4.07% |
| 2016-12-31 | CN¥327.61 Million ≈ $47.94 Million |
-22.21% |
| 2015-12-31 | CN¥421.16 Million ≈ $61.63 Million |
+80.97% |
| 2014-12-31 | CN¥232.72 Million ≈ $34.05 Million |
+41.29% |
| 2013-12-31 | CN¥164.72 Million ≈ $24.10 Million |
+15.76% |
| 2012-12-31 | CN¥142.29 Million ≈ $20.82 Million |
+20.61% |
| 2011-12-31 | CN¥117.97 Million ≈ $17.26 Million |
-11.56% |
| 2010-12-31 | CN¥133.39 Million ≈ $19.52 Million |
-33.04% |
| 2009-12-31 | CN¥199.20 Million ≈ $29.15 Million |
+93.49% |
| 2008-12-31 | CN¥102.95 Million ≈ $15.06 Million |
+21.63% |
| 2007-12-31 | CN¥84.64 Million ≈ $12.39 Million |
+17.89% |
| 2006-12-31 | CN¥71.80 Million ≈ $10.51 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more